Výsledky vyhledávání - "Damian J. McColl"

Akademický článek

Resistance mutations outside the integrase coding region have an effect on human immunodeficiency virus replicative fitness but do not affect its susceptibility to integrase strand transfer inhibitors.

Autor: Jan Weber, Justine D Rose, Ana C Vazquez, Dane Winner, Nicolas Margot, Damian J McColl, Michael D Miller, Miguel E Quiñones-Mateu

Publikováno v: PLoS ONE, Vol 8, Iss 6, p e65631 (2013)

Most studies describing phenotypic resistance to integrase strand transfer inhibitors have analyzed viruses carrying only patient-derived HIV-1 integrase genes (INT-recombinant viruses). However, to date, many of the patients on INSTI-based treatment

Externí odkaz: https://doaj.org/article/cdf2f9aec6404be7b22c7ae4ed2c43b3

Zobrazit plný text záznamu

Virological Outcomes of EVG/COBI/FTC/TDF and EVG/COBI/FTC/TAF in Antiretroviral-Naive HIV-1-Infected Participants with Baseline HIV-1 RNA ≥1,000,000 Copies/ml: A Post Hoc Analysis of Phase III Clinical Trials

Autor: Kirsten L. White, Damian J McColl, Edwin DeJesus, Christian Callebaut, David Piontkowsky, Hui Wang, Martin S. Rhee, Paul E. Sax, Jennifer Demorin, Erin Quirk, Moupali Das, David A. Wohl, Calvin J. Cohen

Publikováno v: Antiviral Therapy. 23:95-99

We address a data gap identified by Adams et al., of virological efficacy outcomes and emergent drug resistance in HIV-1-infected, antiretroviral treatment (ART)-naive participants with baseline (BL) viral loads (VL) >1,000,000 copies/ml. Initial ART

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b9664868d3f15e46847fb12e76282b76
https://doi.org/10.3851/imp3187

Zobrazit plný text záznamu

Switching to the single-tablet regimen of elvitegravir, cobicistat, emtricitabine, and tenofovir DF from non-nucleoside reverse transcriptase inhibitor plus coformulated emtricitabine and tenofovir DF regimens: Week 96 results of STRATEGY-NNRTI

Autor: Andrea Antinori, Jason Flamm, Douglas J. Ward, Damian J McColl, Mark Bloch, William Garner, Thai Nguyen-Cleary, Kristen Andreatta, Juan Berenguer, Javier Szwarcberg, David Piontkowsky, Pierre Côté, Anton Pozniak

Publikováno v: HIV Clinical Trials. 18:141-148

HIV-1-infected, virologically suppressed adults wanting to simplify or change their non-nucleoside reverse transcriptase inhibitor (NNRTI)-based regimens may benefit from switching to the single-tablet regimen of elvitegravir, cobicistat, emtricitabi

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c4b97d43c52227c6c3c88f1131f03aab
https://doi.org/10.1080/15284336.2017.1338844

Zobrazit plný text záznamu

Simplification to single-tablet regimen of elvitegravir, cobicistat, emtricitabine, tenofovir DF from multi-tablet ritonavir-boosted protease inhibitor plus coformulated emtricitabine and tenofovir DF regimens: week 96 results of STRATEGY-PI

Autor: Kristen Andreatta, Javier Szwarcberg, Damian J McColl, Jan van Lunzen, William J. Towner, Raji Swamy, Adriano Lazzarin, Christine Zurawski, Thai Nguyen, Mark T. Nelson, Edwin DeJesus, Jose R. Arribas, Manuela Doroana

Publikováno v: HIV Clinical Trials. 18:118-125

Antiretroviral therapy (ART) simplification to a single-tablet regimen can benefit HIV-1-infected, virologically suppressed, individuals on ART composed of multiple pills.We assessed long-term efficacy and safety of switching to co-formulated elviteg

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::aeede46e74f9334e7bf8ef01c8891225
https://doi.org/10.1080/15284336.2017.1330440

Zobrazit plný text záznamu

Efficacy and safety of elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide in Asian participants with human immunodeficiency virus 1 infection: A sub-analysis of phase 3 clinical trials

Autor: Shinichi Oka, Sasisopin Kiertiburanakul, Ploenchan Chetchotisakd, Khuanchai Supparatpinyo, Chris Nguyen, Amanda Clarke, Roberto Corales, Do Tran, Susan Guo, Anchalee Avihingsanon, Yeon Sook Kim, Moupali Das, David Piontkowsky, Damian J McColl, Winai Ratanasuwan, SangYoun Yang, Ya-Pei Liu, Kiat Ruxrungtham

Publikováno v: HIV researchclinical practice.

Background: The efficacy and safety of a single tablet regimen (STR) of elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF) was analyzed in Phase 3 clinical trials in antiretroviral therapy (ART)-naive and ART-experienced Asian pa

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f08dc2f402b5c83d415a3fd95a420786
https://pubmed.ncbi.nlm.nih.gov/31303140

Zobrazit plný text záznamu

Week 144 Resistance Analysis of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Versus Atazanavir+Ritonavir+Emtricitabine/Tenofovir DF in Antiretroviral-Naïve Patients

Autor: Rima Kulkarni, Michael E. Abram, Damian J. McColl, Tiffany Barnes, Marshall W. Fordyce, Javier Szwarcberg, Andrew K. Cheng, Michael D. Miller, Kirsten L. White

Publikováno v: HIV Clinical Trials. 15:218-230

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::13b9395bbf7721bde04ad9a55040156a
https://doi.org/10.1310/hct1504-218

Zobrazit plný text záznamu

Trends in HIV-1 Reverse Transcriptase Resistance-Associated Mutations and Antiretroviral Prescription Data from 2003–2010

Autor: Mojgan Haddad, Cathy Su, Damian J McColl, Craig S. Gibbs, Bill Guyer, Michael D. Miller

Publikováno v: Antiviral Therapy. 17:993-999

Background The selection of antiretroviral (ARV) drugs for treatment of HIV-1 infection is based on several factors including potency, toxicity, resistance and ease of administration. Emtricitabine (FTC) or lamivudine (3TC), components of recommended

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::565f961f008889232c5faac1b59a848b
https://doi.org/10.3851/imp2266

Zobrazit plný text záznamu

Low level of the K103N HIV-1 above a threshold is associated with virological failure in treatment-naive individuals undergoing efavirenz-containing therapy

Autor: Katyna Borroto-Esoda, Damian J McColl, Nicolas A. Margot, Evguenia S. Svarovskaia, Michael D. Miller, Lijie Zhong, Yun Zhou, Derrick D. Goodman

Publikováno v: AIDS. 25:325-333

BACKGROUND Study GS-01-934 was a randomized open-label phase III study comparing efavirenz and tenofovir/emtricitabine to efavirenz and zidovudine/lamivudine in treatment-naive HIV-1-infected individuals. Through 144 weeks, 50 of 487 participants wit

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fccc1bf218bce7dc2781ed79490a4fe1
https://doi.org/10.1097/qad.0b013e3283427dcb

Zobrazit plný text záznamu

Strand transfer inhibitors of HIV-1 integrase: Bringing IN a new era of antiretroviral therapy

Autor: Damian J. McColl, Xiaowu Chen

Publikováno v: Antiviral Research. 85:101-118

HIV-1 integrase (IN) is one of three essential enzymes (along with reverse transcriptase and protease) encoded by the viral pol gene. IN mediates two critical reactions during viral replication; firstly 3′-end processing (3′EP) of the double-stra

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::04989e3a6ca1586205f78d4ad152243e
https://doi.org/10.1016/j.antiviral.2009.11.004

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání